Abstract: The initial description of Carney complex (CNC) in 1985 included myxomas, spotty skin pigmentation, and endocrine overactivity (of the adrenal, the pituitary, and the testis). In 1997, thyroid neoplasms were found in 3 patients with CNC and involvement of the gland in the syndrome was apparent. Herein, we describe the clinical, pathologic, and follow-up findings in 26 patients with CNC and a disorder of the thyroid gland. The patients were predominantly middle-aged women with an asymptomatic thyroid mass. Four patients had hyperthyroidism, which was caused by follicular hyperplasia in 2 patients and by toxic adenoma in 2 others. Pathologic findings included benign lesions (follicular hyperplasia, nodular hyperplasia, and follicular adenoma) in 16 patients and carcinomas (follicular or papillary) in 10 patients. The follicular carcinomas had unusual features, multifocality, bilaterality, and lymph node metastasis. The tumor was fatal in 3 of 4 patients with a tumor ≥ 3 cm in diameter. One patient had an unusual multifocal microscopic follicular hyperplasia. Detection and treatment of the thyroid neoplasms in patients with CNC requires long-term followup of patients with the syndrome.
I n 1985, Carney et al 1, 2 described the dominantly inherited multitumor syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity, now referred to as Carney complex (CNC). Later, psammomatous melanotic schwannoma, epithelioid blue nevus, and osteochondromyxoma of bone were added to the syndrome. [3] [4] [5] The tumors were infrequent or rare and multifocal in the organ or system affected. Endocrine overactivity resulted from adrenal, pituitary, and testicular hyperplasia and neoplasia.
In 1997, Stratakis et al 6 reported tumors of the thyroid gland in 3 of 53 patients (6%) with CNC: 1 patient had papillary carcinoma, 1 had follicular carcinoma, and 1 had follicular adenoma. The tumors were multiple in 2 patients. These findings showed that thyroid tumors were part of the syndrome. In 2009, Bertherat et al 7 found a thyroid disorder in 88 of 353 patients with CNC (25%); papillary or follicular carcinoma or both occurred in 9 of the 353 patients (2.5%). One patient died of follicular carcinoma. The present investigation was undertaken to study the pathologic findings in the thyroid gland in CNC.
PATIENTS AND METHODS
This study was approved by the Mayo Clinic Institutional Review Board (protocol 979-01). The clinical and pathology records of Mayo Clinic in Rochester, Minnesota, J.A.C.'s files, and records of the National Institutes of Health (NIH) (Bethesda, MD) from January 1999 through June 2016 were searched for patients with CNC who had thyroid gland surgery or who likely had thyroid gland pathology because of thyroid symptoms (thyrotoxicosis). Patient CNC-associated findings and thyroid-related clinical, surgical, and pathologic findings and follow-up information were abstracted from the records. A second search of those records was conducted for patients with CNC and normal thyroid clinical findings who had died of nonthyroid-related causes and whose thyroid gland was available at autopsy for histologic study. The world medical literature from January 1999 through June 2016 was searched for reports of patients with CNC and mention of the thyroid gland.
For the patients identified in the searches, the available thyroid surgical and autopsy histologic slides, pathology reports, and paraffin blocks were obtained. Sections 4 μm thick were cut for hematoxylin-eosin staining, and immunostaining with antibodies was directed against the following: thyroglobulin (Ultraview, CC1, 1/100, 2H11/64E1; Cell Marque); mesothelial cell (HBME-1) (Refine, ER2, 1/40, HBME-1; Dako); cytokeratin 19 (Ultraview, CC1, 1/20, RCK108; Dako); galectin-3 (Ultraview, CC1, 1/75, 9C4; Leica [Novocastro]); PAX8 (Optiview, CC1, 1/50, BC12; Biocare); TTF-1 (Ultraview, CC1, 1/700, 8G7G3/1; Dako); and calcitonin (Ultraview, 1/4000, polyclonal; Dako). The controls were as follows: for thyroglobulin, thyroid (positive) and testis and placenta (negative); for mesothelial cell, thyroid tumor (positive) and normal thyroid (negative); for cytokeratin 19, small intestinal epithelium (positive) and colon and tonsil (negative); for galectin-3, tonsillar macrophages (positive) and tonsillar mantle zone (negative); for PAX8, normal kidney (positive) and kidney stromal cells (negative); for TTF-1, thyroid (positive) and placenta and testis (negative); and for calcitonin, medullary thyroid carcinoma (positive) and normal thyroid (negative).
RESULTS

Clinical
The first search identified 10 patients with CNC who had or likely had thyroid gland pathology (8 women and 2 men; 3 were in Mayo Clinic records, 5 were in J.A.C.'s files, and 2 were in the NIH files). Two patients who had Graves disease and a third who had a nodule that caused thyrotoxicosis were presumed to have thyroid pathology. Patient sex, age at diagnosis of CNC, age at diagnosis of a thyroid disorder, CNC components, and PRKAR1A mutational status are shown in Table 1 . Patients 5 and 8 were mother and daughter. Patient 9 was described previously 6, 9 and is included in the present study because of unusual pathologic features of the thyroid and availability of follow-up.
Clinical thyroid findings, results of thyroid ultrasonography and fine-needle aspiration biopsy studies, preoperative diagnosis, treatment, and pathologic diagnosis for the 10 patients are shown in Table 2 . Patients 3, 6, and 7 had thyrotoxicosis and were treated medically. The thyroid lesions were found in all patients except patient 2 after a diagnosis of CNC was established.
Pathologic findings in the 10 patients included follicular carcinoma (3 patients), follicular adenoma (3 patients, presumed in patient 7), nodular hyperplasia (1 patient), and diffuse follicular hyperplasia (presumed in 2 patients) ( Table 2) . None of the patients had C-cell disease. Findings and follow-up for patients 1, 4, and 9, who had follicular carcinoma, are shown in Table 3 .
Of the 169 literature abstracts identified, 17 (10%) described 18 patients with a thyroid abnormality. The patients' sex, age, CNC components, PRKAR1A mutational status, and thyroid pathologic diagnosis are shown in Table 4 . Of these 18 patients, 15 were asymptomatic, and the thyroid lesions were found on physical examination. One patient (patient 11) had thyrotoxicosis caused by a toxic adenoma; a subtotal thyroidectomy was performed, and 5 years later a follicular carcinoma was found. Another 47 patients (28%) described in the abstracts had normal results on thyroid clinical or sonographic studies. The gland was not referred to in the remaining 105 abstracts (62%).
The second search identified 6 patients with CNC who had clinically normal thyroid glands and died of nonthyroid-related causes; thyroid glands obtained at autopsy were normal histologically (Table 5) .
Pathology
Gross and microscopic findings of lesions and follow-up for patients 1, 4, and 9 are presented in Table 3 along with findings from another 4 patients with follicular carcinoma reported in the literature. Histologic findings in patient 4 are presented in Figure 1 . Immunostaining of the carcinomas in patients 1, 4, and 9 showed cytoplasmic positivity for thyroglobulin (3/3 tumors), nuclear positivity for PAX8 (3/3), nuclear positivity (50% of cells) for HBME-1 (2/3 tumors), scattered cells positive for galectin-3 (3/3), and no staining with cytokeratin 19 and calcitonin (3/3 tumors).
Mutational findings and pathologic diagnoses in the 16 reported patients are shown in Table 4 . Microscopic findings in patient 22 were unusual. The patient, a 13-yearold girl, had a total thyroidectomy for an asymptomatic multinodular goiter. 21 The pathology report mentioned a LCCSCT indicates large-cell calcifying Sertoli cell tumor; PMS, psammomatous melanotic schwannoma; PPNAD, primary pigmented nodular adrenocortical disease.
1.5×1×1-cm tumor. The diagnosis was "multifocal papillary and follicular hyperplasia, atypical." Review of the histologic findings revealed a multinodular goiter, follicular adenoma, and microscopic follicular adenomatosis (Fig. 2) .
DISCUSSION
The components of CNC have emerged over time. Thyroid involvement in the syndrome was reported in 1997, 6 12 years after the first description of CNC, 1 and confirmed more than a decade later. 7 Herein, we have described the clinical, pathologic, and follow-up findings for 26 patients with CNC who had thyroid gland surgery (Tables 1-4 and 6) (including the thyroid adenoma found at autopsy in patient 20). Of the 10 patients identified from the records of Mayo Clinic, J.A.C., and the NIH, 6 had thyroid-related symptoms and 4 had thyrotoxicosis (Table 2) . Of the 16 patients identified from the literature search, 15 were asymptomatic.
The results of the combined study and literature findings showed that a thyroid disorder was an uncommon and late-developing feature of CNC. Most of the patients were asymptomatic women; the female to male ratio was ∼2:1. The patients ranged in age from the second through the sixth decades. The youngest and oldest at operation were 13 and 57 years, respectively; the mean age was 34 years.
Pathologic findings included (1) follicular carcinoma (7 patients, multiple tumors in 2); (2) papillary carcinoma (3 patients); (3) follicular adenoma (7 patients; 1 [patient 22] also had a multinodular goiter and multifocal microscopic papillary and follicular adenomatosis) (Fig. 2) ; and (4) nodular hyperplasia (5 patients). Three patients with hyperthyroidism (patients 3, 6, and 7) did not undergo surgery (2 had Graves disease and 1 had a toxic nodule). Patient 11 had a toxic follicular adenoma at age 54 years; a follicular carcinoma was found 5 years later. Follicular carcinoma was the most serious lesion encountered in the study. Most of the affected patients were middle aged (mean age, 46 y; range, 22 to 59 y). Tumors in 4 patients were large ( ≥ 3 cm in diameter) at discovery and had already metastasized. The neoplasm was multifocal in patients 1 and 9. Clinically, thyroid malignancy was suspected in patients 1 and 4. The tumors that metastasized were 3 cm or larger in diameter. The neoplasm was fatal in 3 of the 7 patients (Table 3) .
Follicular carcinoma accounts for about 20% of all thyroid carcinomas. 30 Typically, it is a single, slow-growing tumor. Lymph node metastasis is found in <10% of cases. 30 Thus, finding the tumor with multifocal and bilateral occurrence and with lymph node metastasis was unexpected and hardly happenstance. The metastases were not responsive to radioiodine ( 131 I) or lenvatinib (a multiple kinase inhibitor that inhibits vascular endothelial growth factor receptors). Papillary carcinoma occurred in 3 patients. Curiously, the follicular tumor was the more common of the 2 carcinomas, the reverse of the frequency in the general population. Four patients had thyrotoxicosis caused by diffuse follicular hyperplasia (presumed in patients 3 and 6) and follicular adenoma (patient 11 and presumed in patient 7). Transient thyrotoxicosis occurred in a patient with CNC not included in the study. 31 Interestingly, ablation of thyroid-specific PRKAR1A in mice resulted in follicular carcinoma and hyperthyroidism. 32 As has been described, several benign and malignant follicular lesions occurred among the 26 patients. This is the multilesional pattern found in the adrenal and testis in CNC; primary pigmented nodular adrenocortical disease, cortical adenoma, and cortical carcinoma occur in the adrenal, and Leydig cell hyperplasia, Leydig cell tumor, and Leydig cell carcinoma occur in the testis. 29, 33 Also, the thyroid lesions were functional and nonfunctional, as are those in the adrenal and testis.
The results indicate the importance of investigating any thyroid nodule in patients with CNC, particularly a nodule > 1 cm. The follicular carcinoma in patient 12 measured 1.5 cm in diameter. More patients with CNC and a thyroid lesion will need treatment as they reach their fourth decade and beyond. Some will have follicular carcinoma, some will have papillary carcinoma, and an exceptional patient will have both tumors. 7 CNC joins the small group of dominantly inherited diseases, including Cowden disease and hereditary familial polyposis, in which nonmedullary thyroid neoplasia occurs. Cowden disease is part of the PTEN hamartoma tumor syndrome caused by heterogenous mutation of the gene located on chromosome 10q23. Hereditary familial polyposis results from mutation of the BMPR1A gene also located on chromosome 10q23. Both disorders include thyroid tumors; follicular thyroid cancer is more common than papillary.
Early detection and surgical resection of follicular and papillary carcinomas offers the best hope of cure. Long-term surveillance of CNC patients is required to detect thyroid carcinomas at an early and curable stage. Clinical or sonographic examination of the gland at annual or biennial cardiac echocardiographic evaluations should improve detection of the lesions.
In summary, we report the clinical and pathologic findings in the thyroid gland of 26 patients with CNC. The findings (1) showed that follicular carcinoma was the most serious lesion affecting the gland in the syndrome; (2) described unusual features of the carcinomas; (3) added follicular hyperplasia (Graves disease) to the pathologic lesions; (4) mentioned a possibly unique type of microscopic multifocal follicular hyperplasia; and (5) added thyrotoxicosis to the clinical findings in the syndrome. Long-term surveillance of patients with CNC is necessary to detect and treat the thyroid lesions, particularly the carcinomas.
